Seleem Sayyar, MD
Psychiatry · Atlanta, GANPI 1508044520
Payments from drug & device makers
Across 40 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$184
- Takeda Pharmaceuticals U.S.A., Inc.$109
- Eisai Inc.$72
- Otsuka America Pharmaceutical, Inc.$54
- Adlon Therapeutics L.p.$49
- Johnson & Johnson$42
- plus $129 from 6 others
What the payments were for
- Food & beverage$639100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 12 | $184 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $109 |
| Eisai Inc. | 5 | $72 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| Adlon Therapeutics L.p. | 3 | $49 |
| Johnson & Johnson | 2 | $42 |
| Jazz Pharmaceuticals Inc. | 2 | $32 |
| Bausch Health US, LLC | 2 | $31 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $13 |
How this compares
$639 in reported general payments places this provider in the 55th percentile of 900 psychiatry providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 151 | $3,550 |
| Lisdexamfetamine Dimesylate | 17 | $3,395 |
| Methylphenidate Er (La)Methylphenidate Hcl | 14 | $1,139 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 31 | $1,014 |
| Methylphenidate Hcl | 47 | $736 |
| Aripiprazole | 22 | $684 |
| Oxcarbazepine | 20 | $561 |
| Olanzapine | 22 | $284 |
| Bupropion XlBupropion Hcl | 13 | $216 |
| Trazodone Hcl | 22 | $207 |
| Hydroxyzine Pamoate | 18 | $196 |
| Quetiapine Fumarate | 15 | $178 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 16 | $165 |
| Fluoxetine Hcl | 17 | $156 |
| Duloxetine Hcl | 12 | $121 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Atlanta
- Robert RiesenbergAtlanta$51.1M
- Saundra Maass-RobinsonAtlanta$11.1M
- David PurselleAtlanta$7.4M
- Bethany DavisAtlanta$4.4M
- Patricio Riva PosseAtlanta$884K
- Kerry ResslerAtlanta$365K
- Boadie DunlopAtlanta$345K
- Michael BurkeAtlanta$328K
- Bryon EvansAtlanta$211K
- Nurul HoqueAtlanta$145K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.